# Regeneron backs $75M series A for antibody upstart Infinimmune

> **Newsylist Open Intelligence Dossier** · First detected: 2026-08-11 18:29 UTC · Category: Business · Sources: 7 · Current Velocity: 4.63

## Intelligence Brief
"Regeneron backs $75M series A for antibody upstart Infinimmune" developed substantial multi-source reporting across the Business sector, tracked across 7 distinct newsrooms by Newsylist.


Key reporting was led by FirstWord Pharma, The Business Journals, BioPharma Dive and Longevity.Technology. Coverage velocity and cross-outlet momentum were measured using Newsylist open coverage telemetry.


Synthesized from multi-source international reporting and live coverage telemetry under Newsylist open intelligence methodology.

## Verified Facts & Key Claims
### What drove coverage for Regeneron backs $75M series A for antibody upstart Infinimmune?
Coverage spiked when 7 independent newsrooms published 7 verified reports during this coverage cycle.

### How did Newsylist track this trend?
Newsylist monitored article arrival rates, source diversity, and cross-outlet validation in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| FirstWord Pharma | Infinimmune bags $75M for atopic dermatitis antibody duo | 2026-08-11 12:00 | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTFBpNjMwdEdMV0lLdTR6b0NQdHpMYlN2TzcxYnpWcjZuTEFKbG5NT2lINnFyZ3dEcUpoY0N4aG1Ld01pTGdKZGF5OWNjWHJMLUFDNVE0?oc=5) |
| The Business Journals | Alameda biotech Infinimmune scores $75 million as it plans first clinical trials | 2026-08-11 12:00 | [Source Link](https://news.google.com/rss/articles/CBMisAFBVV95cUxOb2FRMVBtWFBzOVVES0pjcjVmNVYyUmtwVmRsUjFLN0diSFN6R2JSYVJ6Ui15Y01hZEFBSjVpOFRWalpNT0wwSG13VUVfRGM2VGJ0N0o5QzJ5RkRMTVVKRXRHbkg0ZjNvRXJvZ1BTUjB0THk5TnVSNFJSeC1jd1prbnNPTGpscGowbDNTcHh3RV9lNlFsZXNDaGpCNVdselF2WF9PSF90eVZodEROdWVfdw?oc=5) |
| BioPharma Dive | Chasing Dupixent, a biotech aims to make better antibody drugs for eczema | 2026-08-11 12:00 | [Source Link](https://news.google.com/rss/articles/CBMiogFBVV95cUxOS0V5NWpzLVNCT1lOYXNCb2o2UmxCNzMwTVNkOE85ejBCRUZCR2xLZ204dThod0JFMzZVdnB2V3RUMm1WQzZYR19DQlY4QkI1c052M24tOTJDS3RNdU5pSVRUTGVjUmo5WVM2cDIzN180U1p4dlZKMGdEdlp6VDBHZ2hrTFB5cXRUZ2ZaWHotUTFIbHZqZzB5b1o0R3cxVU1aUkE?oc=5) |
| Longevity.Technology | Re-engineering immune memory for tissue repair | 2026-08-11 12:00 | [Source Link](https://news.google.com/rss/articles/CBMiiAFBVV95cUxQdU1fNlUwNjRXYlJpbXNtdEVEWjFxOXNCWm15TXJQMnJDMFZYVWxXTVEyQ3l6cXFKcElZdkYtSDdGMkJVNmM2MThtRnNSdmU1SW9BMF9qOWtSTEM5TjVlR3B2d0NCRTBpdEdyR2RrRWY4aEM1V3djS253QVRHcHY1UnIzbGdOMW9l?oc=5) |
| Business Wire | Infinimmune Raises $75 Million Series A Financing to Advance Pipeline of Human-Derived Antibodies for Atopic Dermatitis and Inflammatory Disease | 2026-08-11 12:00 | [Source Link](https://news.google.com/rss/articles/CBMiqwJBVV95cUxQTXNmaVRIVHZpVTlmOHYzdUxWZmFZX1UzWmxIcXUwUlNwbW1NSEhWclJ2ek5FanZ0VUs3NDdLaU5hSWZfRjBrV3pfbXBLdFZRZFlNcVd4Q1g1d3ozeXdHZmRtOW45aVpacktvWmhJaW1kQ1BmZmxFYzFnUlFfWXlrdFlpQnA5emRNdE9OZ205YUpnQl9RWGNZOEdCS2FhS3dLNU9CUVN5Z19yb3BCSjFQVWZLc09ScFduODIyMWNramxkS3JheEpCbnVHdXdkcThwZ2ZtR3JfOWk3SVl5YU9OeGl1c3ZjdDhIYTZBUmlYaXBhcGtDZmhmanhmVTFZMFFvS3lKY2lLRExaX3J2OWppRExRNUFXU0dVdmlUdmxEM1YxYzJPaE16eTRiVQ?oc=5) |
| Endpoints News | Lilly paid $2B upfront for vaccine biotechs; Infinimmune raises $75M | 2026-08-11 12:00 | [Source Link](https://news.google.com/rss/articles/CBMikwFBVV95cUxPeVFFZmFsajNpR3h2VnZVcUctZ3hMZUNBUkVhR1JlaDFoVTlYR0FUUGVEWVBJMWFXSi1WM3cwZms3OGhTX1RzNFhjZnBqLUVGUV9zZ3BDTFo1NDNPYVQyazFTbVptLUt4eFVwV0VBYjhfQnVJcVN1Wk1TZU1RREEzQ01iQUk2Q1VZaEo0Ykpid0xZN28?oc=5) |
| Fierce Biotech | Regeneron backs $75M series A for antibody upstart Infinimmune | 2026-08-11 12:00 | [Source Link](https://news.google.com/rss/articles/CBMimAFBVV95cUxPTXB0Q2NuRkVraGNzcEpOb2VuY0ZNUlNocWgxbDlLUXFyQTM5QU53T2FTZWNKVzFVMXRvN1c1QnltOUpiOHF2dTVLVlZTOXc0Ymhac3pMcXJPRUdOMW5DdWJtWHk1QzVWZXFQQWc3R1lnZzlrSWVrZnhHS0pNa2hzNkdCSjBLT2QzZ3JWWDF0Z29KRzhiQUd2Qg?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-08-11/regeneron-backs-75m-series-a-for-antibody-upstart-infinimmune*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*